Evidence map›Paper›PMID 34032928›Full record

ArticleActa diabetologica2021

Usefulness of skin advanced glycation end products to predict coronary artery calcium score in patients with type 2 diabetes.

Alejandra Planas, Olga Simó-Servat, Jordi Bañeras, Mónica Sánchez, Esther García, Ángel M Ortiz, Marisol Ruiz-Meana, Cristina Hernández, Ignacio Ferreira-González, Rafael Simó

Abstract read
PubMed Publisher
In one paragraph

Article in Acta diabetologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Is skin autofluorescence a novel non-invasive marker in diabetes? A systematic review and meta-analysis of case-control studies.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2023
    Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Alejandra Planas *Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Autonomous University of Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
Olga Simó-Servat *Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Autonomous University of Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
Jordi BañerasCardiology Department, Vall d'Hebron University Hospital and Research Institute, Autonomous University of Barcelona, Barcelona, Spain.
Mónica SánchezDiabetes and Metabolism Research Unit, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Autonomous University of Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
Esther GarcíaDiabetes and Metabolism Research Unit, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Autonomous University of Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
Ángel M OrtizDiabetes and Metabolism Research Unit, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Autonomous University of Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
Marisol Ruiz-MeanaCardiology Department, Vall d'Hebron University Hospital and Research Institute, Autonomous University of Barcelona, Barcelona, Spain.
Cristina HernándezDiabetes and Metabolism Research Unit, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Autonomous University of Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
Ignacio Ferreira-GonzálezCardiology Department, Vall d'Hebron University Hospital and Research Institute, Autonomous University of Barcelona, Barcelona, Spain.
Rafael SimóDiabetes and Metabolism Research Unit, Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Autonomous University of Barcelona, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain. rafael.simo@vhir.org.ORCID http://orcid.org/0000-0003-0475-3096
Universitat Autònoma de Barcelona · ESHebron University · PS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe early identification of type 2 diabetic (T2D) patients at risk of developing coronary artery disease (CAD) remains a challenge. The coronary artery calcium score (CACs) is considered the most sensitive tool for assessing CAD risk in diabetic population, and the identification of a more targeted population in which the CACs would be more cost-efficient seems warranted. The accumulation of advanced glycation end products plays an important role in the pathogenesis of cardiovascular disease (CVD) in patients with diabetes. The aim of this study was to evaluate whether the assessment of skin autofluorescence (SAF) could be useful tool to identify those diabetic patients in whom CACs assessment should be prioritized.

methodsProspective case-control study, comprising 156 subjects with T2D with no history of clinical CVD and 52 non-diabetic subjects matched by age. A value of CACs ≥ 400 Agatston Units (AU) was considered as "high CVD risk." Logistic regression analysis to predict a CACs ≥ 400 AU was performed. Sensibility and specificity were calculated using the optimal cutoff point based on ROC curve.

resultsT2D patients had higher value of SAF compared to controls (p = 0.011). Among subjects with diabetes, 122 presented CACs < 400 AU and 35 CACs ≥ 400 AU. SAF values were significantly higher among the group with CACs ≥ 400AU compared to patients with CACs < 400 (2.96 ± 0.86 vs. 2.59 ± 0.57; p = 0.0035). The logistic regression analysis showed that age, HDL-cholesterol and SAF values were independently related to CACs ≥ 400UA.

conclusionOur finding suggests that SAF could be useful in selecting T2D patients in whom the screening for CAD by means of CACs assessment would be more cost-effective.

Indexed as

Diabetes Mellitus, Type 2Glycation End Products, AdvancedCalciumCase-Control StudiesCoronary VesselsHumansRisk FactorsCalciumGlycation End Products, AdvancedAdvanced glycation end productsCoronary artery calcium scoreSkin autofluorescenceSubclinical cardiovascular diseaseType 2 diabetes

Identifiers

PMID34032928
OpenAlexW3165320871

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.